Where this sits against the prescription market
The usual comparison here is between a research chemical with no evidence and a prescription medicine with a full dossier. Kisspeptin falls between them in a way almost nothing else covered on this site does.
It has the research. Roughly 45 registered studies, about 26 completed, four in Phase 3, and several thousand PubMed records on the peptide and its receptor. The sponsors are hospitals and universities, not vendors: an individual academic investigator and Massachusetts General Hospital hold the largest blocks, with Imperial College London and university hospitals elsewhere adding more.
What it does not have is the second half. No regulator has approved it as a marketed medicine, so there is no label, no authorised quantity and no pharmacy that can dispense it.
What a hospital trial establishes, and what it does not
The programme is reproductive endocrinology. Kisspeptin drives GnRH release and, downstream of that, luteinising hormone. The clinical questions follow: delayed puberty, hypogonadotropic hypogonadism, fertility, and use as a trigger in assisted reproduction.
Quantities in those studies were chosen to produce a hormonal response an assay would read, in a defined patient group, with clinical supervision and an endpoint fixed in advance. That is a genuine dosing context and it is the reason published human figures exist at all.
It is also why those figures do not travel. A quantity that reliably moves LH in a patient with a specific endocrine diagnosis is a statement about that setting. It is not a general instruction, and no trial in the programme was designed to make it one.
The gap between a trial programme and a label
This is the distinction worth taking away, because it is the one most pages blur. A completed trial produces evidence. A label produces authorisation, and only a regulator can issue it after reviewing the dossier and being accountable for the conclusion.
Kisspeptin has the first and not the second. So a kisspeptin dosage chart works from better source material than nearly anything else in this category, while still having no authorised figure to restate.
The practical test on any such chart is whether each number carries the population and endpoint it came from. For most compounds that test fails because no study exists to cite. Here the studies exist, so an unattributed figure is a choice rather than a limitation.